DIFFERENTIATED APPROACH TO THE SELECTION OF VITAMIN D PREPARATIONS FOR THE TREATMENT OF OSTEOPOROSIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the need for a differentiated approach to the selection of vitamin D preparations for the treatment of osteoporosis (OP). Data on the physiological role of vitamin D and the main causes of deficient states are presented. The features of the metabolism of native and active forms of vitamin D are described, including age-depending features. It is noted that alfacalcidol due to the absence of renal metabolism demonstrates greater clinical efficacy compared with native vitamin D in the treatment of various types of OP with a similar safety profile. Alfacalcidol as monotherapy is included in the clinical recommendations for the treatment of OP in contrast to native vitamin D, because it has demonstrated a more pronounced effect in terms of increasing bone mineral density, reducing the risk of falls, reducing the risk of fractures, and significantly reducing pain syndrome. The broad options in the selection of individual doses of Alfacalcidol (Alpha D3®-Teva) allows to choose the appropriate dosage for each patient with osteoporosis, taking into account the effectiveness and tolerability This fact, along with the prevention of new fractures, elimination of pain syndrome and reducing the risk of falls contributes to improving the quality of life of patients of all ages.

Full Text

Restricted Access

About the authors

I. S Dydykina

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"

Email: dydykina_is@mail.ru
PhD, Leading Researcher at the Laboratory for the Evaluation of the Safety ofAntirheumatic Drugs

P. S Kovalenko

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"

A. A Kovalenko

FSAEI HE “First Moscow State Medical University n.a. I.M. Sechenov" of RMH

References

  1. Беневоленская Л.И., Лесняк О.М. Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. М., 2005. С. 146-63.
  2. Беневоленская Л.И., Лесняк О.М. Остеопороз. 2-е изд., перераб. и доп. М., 2009.
  3. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., Дзеранова Л.К., Каронова Т.Л., Ильин А.В., Мельниченко Г.А., Дедов И.И. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы эндокринологии. 2016;6 2(4):60-84.
  4. Бахтиярова С.А., Лесняк О.М. Дефицит витамина D среди пожилых людей. Общая врачебная практика. 2004;1:26-32.
  5. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A., Heaney R.P., Murad M.H., Weaver C.M.; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011;96(7):1911-30.
  6. Henderson L., Irving K., Gregori J., et al. The National Diet and Nutrition Survey: Adults aged 19-64 years. Volume 3: Vitamin and mineral intake and urinary analysis. The Stationery Office. London, 2003.
  7. Jones G. Pharmacokinetics of vitamin D toxicity. Am. J. Clin. Nutr. 2008;88:582-86.
  8. Спиричев В.Б. Витамины, витаминоподобные и минеральные вещества: Справочник. М., 2004. 240 с.
  9. Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации. Метод. Рекомендации. МР 2.3.1.2432-38.
  10. Dawson-Hughes B., Mithal A., Bonjour J.P., Boonen S., Burckhardt P., Fuleihan G.E., Josse R.G., Lips P., Morales-Torres J., Yoshimura N. IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int. 2010;21(7):1151-54.
  11. Gómez de Tejada Romero M.J., Sosa Hennríquez M., Del Pino Montes J., Jódar Gimeno E., Quesada Gómez J.M., Cancelo Hidalgo M.J., Diaz Curiel М., Mesa Ramos M., Muñoz Torres M., Carpintero Benítez P., Navarro Ceballos C., Valdés y Llorca C., Giner Ruiz V., Blázquez Cabrera J.A., Garcia Vadillo J.A., Martínez Rodríguez M.E., Pena Arrebola A., Palacios Gil-Antunano S. Position document on the requirements and optimum levels of vitamin D. Rev. Osteoporos. Metab. Miner. 2011;3(1):53-64.
  12. Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B., Orav J.E., Stuck A.E., Theiler R., Wong J.B., Egli A., Kiel D.P., Henschkowski J. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009;339:b3692.
  13. Инструкция по медицинскому применению препарата Альфа Д-3® Тева, ЛСР-007813/10.
  14. Bischoff-Ferrari H.A., Shao A., Dawson-Hughes B., Hathcock J., Giovannucci E., Willett W.C: Benefit-risk assessment of vitamin D supplementation. Osteoporos Int. 2010;21(7):1121-32.
  15. Лесняк О.М. Эффективность и безопасность альфакальцидола в лечении остеопороза и предупреждении переломов: обзор современных данных Эффективная фармакотерапия. Ревматология, травматология и ортопедия. 2014;1(10).
  16. Шварц Г.Я. Дефицит витамина D и его фармакологическая коррекция. РМЖ. 2009;17(7):477-86.
  17. Белая Ж.Е., Рожинская Л.Я. Витамин D в терапии остеопороза: его роль в комбинации с препаратами для лечения остеопороза, внескелетные эффекты. Эффективная фармакотерапия. 2013;2:14-29.
  18. Richy F., Dukas L., Schacht E. Differential effects of D-Hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcific Tissue International. 2008;82:102-7.
  19. Del Valle E., Negri A.L., Fradinger E., Canalis M., Bevione P., Curcelegui M., Bravo M., Puddu M., Marini A., Ryba J., Peri P., Rosa Diez G., Sintado L., Gottlieb E. Weekly high-dose ergocalciferol to correct vitamin D deficiency/insufficiency in hemodialysis patients: A pilot trial. Hemodial. Int. 2014 Sep 17.
  20. Mager D.R., Jackson S.T., Hoffmann M.R., Jindal K., Senior P.A. Vitamin D supplementation and bone health in adults with diabetic nephropathy: the protocol for a randomized controlled trial. BMC. Endocr. Disord. 2014;14:66.
  21. Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B., Orav J.E., Stuck A.E., Theiler R., Wong J.B., Egli A., Kiel D.P., Henschkowski J. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009;339:b3692.
  22. Ершова О.Б., Белова К.Ю. Остеопороз. Возможности профилактики системного остеопороза. Consilium medicum. 2005;07(8).
  23. Лесняк О.М., Баранова И.А., Торопцова Н.В. Клинические рекомендации «Диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше». Ярославль, 2013, 48 с.
  24. Richy F., Schacht E., Bruyere O., Ethgen O., Gourlay M., Reginster J.Y. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures- a comparative meta-analysis. Calcif Tissue Int. 2005;76:176-86.
  25. Ringe D., Dorst A., Faber H., Schlacht E., et al. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol. Int. 2004; 24(2):63-70.
  26. Richy F., Dukas L., Schacht E. Differential effects of D-hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcif Tissue Int. 2008;82(2):102-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies